Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded company in the Unknown sector. Across all available filings, 12 corporate insiders have executed 153 transactions totaling $147.8M, demonstrating a bullish sentiment with $22.6M in net insider flow. The most recent transaction on Jun 27, 2025 involved a sale of 1,176,332 shares valued at $4.9M.
No significant insider buying has been recorded for CRVS in the recent period.
No significant insider selling has been recorded for CRVS in the recent period.
Based on recent SEC filings, insider sentiment for CRVS is bullish with an Insider Alignment Score of 58/100 and a net flow of $22.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Corvus Pharmaceuticals, Inc. (CRVS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 12 insiders are actively trading CRVS stock, having executed 153 transactions in the past 90 days. The most active insider is Peter A. Thompson (Executive), who has made 25 transactions totaling $38.8M.
Get notified when executives and directors at CRVS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | A. Thompson Peter | Executive | Sale | 1,176,332 | $4.16 | $4.9M | Large |
| Jun 27, 2025 | A. Thompson Peter | Executive | Exercise | 1,397,684 | $3.50 | $4.9M | Large |
| Jun 27, 2025 | Llc Orbimed Advisors | Executive | Exercise | 1,397,684 | $3.50 | $4.9M | Large |
| Jun 27, 2025 | Llc Orbimed Advisors | Executive | Sale | 1,176,332 | $4.16 | $4.9M | Large |
| May 10, 2024 | A. Miller Richard Md | Executive | Gift | 302,016 | $N/A | $0 | |
| May 6, 2024 | A. Miller Richard Md | Executive | Purchase | 577,634 | $1.73 | $999.3K | Large |
| May 6, 2024 | Benton Jones William | Executive | Purchase | 20,000 | $1.73 | $34.6K | |
| May 15, 2023 | Grais Linda | Executive | Purchase | 10,000 | $2.45 | $24.5K | |
| Dec 20, 2022 | Benton Jones William | Executive | Purchase | 20,000 | $0.79 | $15.8K | |
| Dec 14, 2022 | A. Miller Richard Md | Executive | Purchase | 10,000 | $0.78 | $7.8K | |
| Dec 14, 2022 | Lea Leiv | Executive | Purchase | 4,000 | $0.84 | $3.4K | |
| Dec 13, 2022 | A. Miller Richard Md | Executive | Purchase | 50,000 | $0.74 | $37.0K | |
| Dec 13, 2022 | Lea Leiv | Executive | Purchase | 30,000 | $0.74 | $22.2K | |
| Sep 28, 2022 | A. Miller Richard Md | Executive | Purchase | 25,000 | $0.76 | $19.0K | |
| Sep 20, 2022 | A. Miller Richard Md | Executive | Purchase | 12,300 | $0.81 | $10.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 112 | $85.2M | 54.1% |
Sale(S) | 11 | $62.6M | 39.7% |
Exercise (Options)(X) | 2 | $9.8M | 6.2% |
Gift(G) | 3 | $0 | 0.0% |
Conversion(C) | 25 | $0 | 0.0% |
Insider activity at Corvus Pharmaceuticals, Inc. shows mixed signals across all time. While $85.2M in purchases indicates some executive confidence,$62.6M in sales balances the picture, resulting in a modest net flow of $22.6M.12 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Peter A. Thompson, has transacted $38.8M during this period.